At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 167 enrolled
Drug / intervention
Taxotere/Docetaxel +2 moredrug
Likely dose
AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cyclesAI-extracted
Key inclusion· 4
- ✓Female patients only
- ✓Primary breast cancer ≥3 cm, surgically operable
- ✓Age > 18 years
- ✓WHO performance status <2
Key exclusion· 6
- ✕Metastatic breast cancer
- ✕Prior taxane or anthracycline chemotherapy for malignancy
- ✕Grade ≥2 peripheral neuropathy
- ✕Severe cardiac disease: heart failure, MI, severe CAD, or uncontrolled hypertension
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Multicenter Trial of Neoadjuvant Taxotere (T) and Adriamycin/Cytoxan (Ac): A Validation
In Brief
A Phase 2 clinical trial evaluating Taxotere/Docetaxel, Adriamycin/Cytoxan, and 1 other intervention for Breast Cancer. Completed, enrolled 167 participants across 1 site.
Detailed Summary
The purpose of this study is to learn if the biomarker information obtained (learned or received) from the earlier studies can tell us whether or not Taxotere and/or Adriamycin/Cytoxan can cause tumors to become smaller.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsBaylor College of Medicine
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2004
First PostedSep 2005
Primary CompletionOct 2016
Study CompletionOct 2016
TodayJul 2026
First PostedSep 21, 2005
Enrollment StartSep 1, 2004
Primary CompletionOct 1, 2016
Study CompletionOct 10, 2016
TodayJul 2, 2026
Enrollment to primary: 12.1 yearsPosted 20.8 years ago
Interventions
Taxotere/Docetaxeldrug
Taxotere
Adriamycin/Cytoxandrug
Adriamycin/Cytoxan
doxorubicindrug
AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.